臨床研究等提出・公開システム

A pharmacodynamic study of TS-172 in healthy adult male subjects

A pharmacodynamic study of TS-172 in healthy adult male subjects

Seiji Mita

Taisho Pharmaceutical Co., LTD.

3-24,1, Takada, Toshima-Ku, Tokyo

shu_chiken@taisho.co.jp

Development Management Development Headquarters

Taisho Pharmaceutical Co., LTD.

TOSHIMA-KU,TOKYO 170-8633 JAPAN

+81-3-3985-1118

shu_chiken@taisho.co.jp

Not Recruiting

Aug. 05, 2025

Interventional

randomized controlled trial

open(masking not used)

uncontrolled control

crossover assignment

treatment purpose

1. Japanese healthy adult males whose age is >=18 and <40 years at the time of obtaining informed consent
2. Subjects whose body mass index is >=18.5 and <25.0 at the screening test
3. Subjects who are judged by a principal investigator or a sub-investigator to be eligible for participation in the study based on the results at the screening test and before administration of the drugs used in the study
4. Subjects who have been informed of the clinical trial, understand the details of the trial, and give their written consent prior to participation in the trial

1. Subjects with medical history ineligible for participation in the study such as of respiratory, cardiovascular, gastrointestinal, hepatic, renal, urologic, endocrine, metabolic, hematologic, immunologic, dermatologic, neurologic, or psychiatric diseases
2. Subjects with medical history of disease (e.g., stomach or intestinal ulcers) or surgery (e.g., gastrectomy, gastric bandage, gastric bypass) that may affect the absorption of the drugs used in the study
3. Subjects who have been hospitalized with any treatment or undergone surgery within 12 weeks prior to receiving the drugs used in the study
4. Subjects with medical history of drug allergies (limited to severe symptoms such as anaphylaxis) or significant allergic predispositions (e.g., asthma that requires treatment)
5. Subjects who have used medications (including over-the-counter drugs) within 2 weeks prior to receiving the drugs used in the study

Male

Hyperphosphatemia

Repeated oral administration of TS-172 20mg immediately before or after meals in each period

Urinaly excretion of phosphorus and urinaly excretion of sodium

+81-92-283-7701

July. 31, 2025

No

none